Genic (Korea) Performance
| 123330 Stock | KRW 22,250 2,390 12.03% |
On a scale of 0 to 100, Genic holds a performance score of 10. The company retains a Market Volatility (i.e., Beta) of 0.61, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Genic's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genic is expected to be smaller as well. Please check Genic's coefficient of variation, jensen alpha, and the relationship between the downside deviation and standard deviation , to make a quick decision on whether Genic's current trending patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Genic Co are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Genic sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | 12.1 B |
Genic |
Genic Relative Risk vs. Return Landscape
If you would invest 1,485,000 in Genic Co on September 20, 2024 and sell it today you would earn a total of 740,000 from holding Genic Co or generate 49.83% return on investment over 90 days. Genic Co is generating 0.8312% of daily returns and assumes 6.1383% volatility on return distribution over the 90 days horizon. Simply put, 54% of stocks are less volatile than Genic, and 84% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Genic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genic Co, and traders can use it to determine the average amount a Genic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1354
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 123330 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.14 actual daily | 54 54% of assets are less volatile |
Expected Return
| 0.83 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Genic is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genic by adding it to a well-diversified portfolio.
Genic Fundamentals Growth
Genic Stock prices reflect investors' perceptions of the future prospects and financial health of Genic, and Genic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genic Stock performance.
| Return On Equity | -18.36 | |||
| Return On Asset | -0.02 | |||
| Profit Margin | (0.06) % | |||
| Operating Margin | (0.04) % | |||
| Current Valuation | 68.82 B | |||
| Shares Outstanding | 6.85 M | |||
| Price To Earning | 30.99 X | |||
| Price To Sales | 0.70 X | |||
| Revenue | 38.41 B | |||
| EBITDA | 986.78 M | |||
| Cash And Equivalents | 17.19 B | |||
| Total Debt | 10.3 B | |||
| Debt To Equity | 1.06 % | |||
| Book Value Per Share | 9,099 X | |||
| Cash Flow From Operations | 3.32 B | |||
| Total Asset | 45.41 B | |||
| Retained Earnings | 33.78 B | |||
| Current Asset | 41.55 B | |||
| Current Liabilities | 20.92 B | |||
About Genic Performance
By analyzing Genic's fundamental ratios, stakeholders can gain valuable insights into Genic's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Genic Co., Ltd. researches, develops, manufactures, and sells hydrogel mask packs in South Korea and internationally. The company was founded in 2001 and is based in Seongnam-si, South Korea. Genic is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about Genic performance evaluation
Checking the ongoing alerts about Genic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genic is way too risky over 90 days horizon | |
| Genic appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 38.41 B. Net Loss for the year was (4.33 B) with profit before overhead, payroll, taxes, and interest of 9.1 B. | |
| About 25.0% of the company shares are owned by insiders or employees |
- Analyzing Genic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genic's stock is overvalued or undervalued compared to its peers.
- Examining Genic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genic's stock. These opinions can provide insight into Genic's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genic Stock analysis
When running Genic's price analysis, check to measure Genic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genic is operating at the current time. Most of Genic's value examination focuses on studying past and present price action to predict the probability of Genic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genic's price. Additionally, you may evaluate how the addition of Genic to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |